Yoon Jun 4

What Happened
CFO Yoon Jun received equity awards from Structure Therapeutics on March 19, 2026. The filing shows two acquisitions: 104,085 ordinary shares (acquired, $0) and 128,892 derivative shares (acquired, $0) — a total of 232,977 shares granted per the Form 4. The derivative grant is identified as restricted stock units (RSUs), not an open-market purchase or sale.

Key Details

• Transaction date: March 19, 2026; Form 4 filed March 23, 2026. No late-filing flag indicated in the provided data.
• Grants reported at $0 acquisition price (typical for compensation awards as reported on Form 4).
• Award breakdown: 104,085 ordinary shares (direct award) + 128,892 RSUs (derivative) = 232,977 total shares.
• RSU vesting (per filing footnote): RSUs represent a contingent right to receive one Ordinary Share each and "vest 1/4th annually on each anniversary of March 1, 2026," subject to continued service.
• ADS note: Ordinary Shares may be represented by American Depositary Shares (ADSs); one ADS = three Ordinary Shares (per filing).
• Some holdings may be held via The Yoon Family Trust (footnote reference).
• Shares owned after the transaction are not specified in the excerpt provided.

Context
The derivative portion consists of RSUs, which do not deliver shares until they vest and thus are contingent on continued service. These grants are compensation awards (not purchases or sales) and were reported at $0 acquisition price on the Form 4. For investors, awards signal company compensation/retention activity but are not the same as an insider buying shares on the open market.